<DOC>
	<DOC>NCT01573351</DOC>
	<brief_summary>The purpose of this study is to assess efficacy, as determined by the proportion of subjects with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C virus (HCV) Ribonucleic acid (RNA) &lt; Limit of quantitation (LOQ) at post-treatment Week 12.</brief_summary>
	<brief_title>Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)</brief_title>
	<detailed_description>- ASV = Asunaprevir (BMS-650032) - DCV = Daclatasvir (BMS-790052) - Peg = Peg-interferon Alfa-2a (PegIFN) - Rib = Ribavirin (RBV)</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Males and females, ≥ 18 years of age HCV Genotype 1 or 4 who previously failed treatment with Peginterferon alfa2a or peginterferon alfa2b and Ribavirin (P/R), classified as previous null and partial responders based on previous therapy HCV RNA ≥ 10,000 IU/mL Seronegative for Human immunodeficiency virus (HIV) and Hepatitis B surface antigen (HBsAg) Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population) Prior treatment of HCV with HCV direct acting antiviral (DAA) Evidence of a medical condition contributing to chronic liver disease other than HCV Evidence of decompensated liver disease including, but not limited to, a history or presence of ascites, bleeding varices, or hepatic encephalopathy Diagnosed or suspected hepatocellular carcinoma or other malignancies Uncontrolled diabetes or hypertension Total bilirubin ≥ 34 μmol/L (or ≥ 2 mg/dL) unless subject has a documented history of Gilbert's disease Alanine aminotransferase (ALT) ≥ 5x Upper limit of normal (ULN) Albumin &lt; 3.5 g/dL (35 g/L) Alpha Fetoprotein (AFP) &gt; 100 ng/mL (&gt;82.6 IU/mL) or ≥ 50 and ≤ 100 ng/mL requires a liver ultrasound and subjects with findings suspicious of Hepatocellular carcinoma (HCC) are excluded Absolute neutrophil count (ANC) &lt; 1.5 x 1000,000,000 cells/L (&lt; 1.2 x 1000,000,000 cells/L for Black/AfricanAmericans) Platelets &lt; 90 x 1000,000,000 cells/L Hemoglobin &lt; 12 g/dL for females or &lt; 13 g/dL for males Any criteria that would exclude the subject from receiving P/R</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>